INTERVENTION 1:	Intervention	0
Prevention (Acolbifene Hydrochloride)	Intervention	1
hydrochloride	CHEBI:36807	23-36
Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.	Intervention	2
hydrochloride	CHEBI:36807	33-46
acolbifene hydrochloride: Given orally	Intervention	3
hydrochloride	CHEBI:36807	11-24
Inclusion Criteria:	Eligibility	0
Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group	Eligibility	1
age	PATO:0000011	66-69
group	CHEBI:24433	70-75
Premenopausal	Eligibility	2
More than 6 months since initiating or discontinuing oral contraceptives	Eligibility	3
At increased risk for breast cancer, as indicated by >= 1 of the following risk factors:	Eligibility	4
breast cancer	DOID:1612	22-35
BRCA1/2 mutation characterized as deleterious or of uncertain significance	Eligibility	5
Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ	Eligibility	6
ductal carcinoma in situ	HP:0030075,DOID:0060074	35-59
lobular carcinoma in situ	HP:0030076,DOID:3010	64-89
Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia	Eligibility	7
aspiration	HP:0002835	37-47
Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:	Eligibility	8
family history	HP:0032316	0-14
breast cancer	DOID:1612	42-55
>= 4 relatives with breast cancer	Eligibility	9
breast cancer	DOID:1612	20-33
>= 2 relatives diagnosed with breast cancer at  50 years of age	Eligibility	10
breast cancer	DOID:1612	30-43
age	PATO:0000011	60-63
Breast and ovarian cancer diagnosed in same relative	Eligibility	11
breast	UBERON:0000310	0-6
ovarian cancer	DOID:2394	11-25
No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA	Eligibility	12
breast cancer	DOID:1612	17-30
menstrual cycle	GO:0044850	84-99
Exhibits hyperplasia with or without atypia (Masood score >= 14) with >= 500 cells AND Ki-67 positivity >= 2% by RPFNA performed within 6 months prior to initiation of study drug	Eligibility	13
drug	CHEBI:23888	174-178
Estimated visual mammographic breast density category >= 5% on mammogram performed within 6 months prior to initiation of study drug	Eligibility	14
breast	UBERON:0000310	30-36
drug	CHEBI:23888	128-132
Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits	Eligibility	15
blood	UBERON:0000178	182-187
Absolute granulocyte count > 1,000/mm^3	Eligibility	16
Platelets > 100,000/mm^3	Eligibility	17
Hemoglobin > 10 g/dL	Eligibility	18
hemoglobin	CHEBI:35143	0-10
Bilirubin < 2.0 mg/dL	Eligibility	19
AST < 2 times upper limit of normal (ULN)	Eligibility	20
Albumin > 3.0 g/dL	Eligibility	21
Creatinine < 1.5 mg/dL	Eligibility	22
creatinine	CHEBI:16737	0-10
Alkaline phosphatase < 2 times ULN	Eligibility	23
phosphatase	GO:0016791,BAO:0000295	9-20
Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment	Eligibility	24
patient	HADO:0000008,OAE:0001817	52-59
aspiration	HP:0002835	129-139
Fertile patients must use effective contraception during and for 3 months after completion of study treatment	Eligibility	25
Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)	Eligibility	26
calcium	CHEBI:22984,BAO:0000874	38-45
calcium	CHEBI:22984,BAO:0000874	100-107
vitamin d	CHEBI:27300	50-59
vitamin d	CHEBI:27300	119-128
Negative pregnancy test prior to receiving study agent	Eligibility	27
Exclusion Criteria	Eligibility	28
pregnant or nursing	Eligibility	29
nursing within the past 6 months	Eligibility	30
Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)	Eligibility	31
osteoporosis	HP:0000939,DOID:11476	6-18
severe	HP:0012828	22-28
osteopenia	HP:0000938	29-39
History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes	Eligibility	32
history	BFO:0000182	0-7
endometriosis	HP:0030127,DOID:289	23-36
pain	HP:0012531	49-53
hot flashes	HP:0031217	87-98
History of deep venous thrombosis	Eligibility	33
history	BFO:0000182	0-7
deep venous thrombosis	HP:0002625	11-33
History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent	Eligibility	34
history	BFO:0000182	0-7
Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA	Eligibility	35
condition	PDRO:0000129	6-15
patient	HADO:0000008,OAE:0001817	95-102
Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)	Eligibility	36
year	UO:0000036	12-16
anastrozole	CHEBI:2704	64-75
exemestane	CHEBI:4953	77-87
letrozole	CHEBI:6413	92-101
estrogen	CHEBI:50114,BAO:0000760	116-124
receptor	BAO:0000281	125-133
tamoxifen citrate	CHEBI:9397	152-169
raloxifene	CHEBI:8772	171-181
hydrochloride	CHEBI:36807	197-210
Other concurrent chemopreventive agents	Eligibility	37
Concurrent anticoagulants	Eligibility	38
Other concurrent investigational agents	Eligibility	39
Bilateral breast implants	Eligibility	40
bilateral	HP:0012832	0-9
breast	UBERON:0000310	10-16
Outcome Measurement:	Results	0
Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months	Results	1
breast	UBERON:0000310	28-34
Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.	Results	2
breast	UBERON:0000310	78-84
aspiration	HP:0002835	145-155
Time frame: Baseline to 6 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Prevention (Acolbifene Hydrochloride)	Results	5
hydrochloride	CHEBI:36807	40-53
Arm/Group Description: Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.	Results	6
hydrochloride	CHEBI:36807	56-69
acolbifene hydrochloride: Given orally	Results	7
hydrochloride	CHEBI:36807	11-24
Overall Number of Participants Analyzed: 25	Results	8
Median (Inter-Quartile Range)	Results	9
median	BAO:0002174	0-6
range	LABO:0000114	23-28
Unit of Measure: percentage of positive cells  -3.0        (-20.2 to 2.8)	Results	10
Adverse Events 1:	Adverse Events	0
Total: 0/25 (0.00%)	Adverse Events	1
